Leveraging the Lymphatic System to Treat ADHF
The WhiteSwell Therapy System is an investigational device not currently approved in the United States or in the European Union.
Its use is limited to investigational use in clinical trials.
Breadth of Lymphatic System
Chief Executive Officer
Eamon Brady is the CEO of WhiteSwell, leading the charge to develop an innovative new therapy for Acute Decompensated Heart Failure by drawing upon the tissue drainage power of the body’s own lymphatic system. He honed his experience in science-driven device development as founder and CEO of Neuravi, where he built a company which treated over 5,000 acute ischemic stroke patients before it was acquired by Johnson and Johnson. He was also a founding member and head of R&D at MedNova Ltd, a company that pioneered carotid stenting and was acquired by Abbott Vascular. Eamon is passionate about bringing medical therapies to market that impact patients with poor prognostic outlook and he sees team building and technological innovation as critical to better patient outcomes. When he isn’t encouraging his team to challenge themselves to continuously improve, Eamon relaxes by working the land in his home near Galway.
Chief Financial Officer
Seán Mac Réamoinn is the CFO of WhiteSwell, guiding the investment in the company to create value and drive growth. An experienced business leader with a specific interest in delivering outstanding shareholder returns for ambitious, high-growth businesses, Seán has led more than 20 corporate transactions from financings, through to business sales and initial public offerings. Seán was most recently CFO of Neuravi, closing series B and debt financing rounds prior to acquisition by Johnson & Johnson, whilst also playing a central role in the company’s successful commercial evolution. A fellow of the Institute of Chartered Accountants, he previously worked in high growth technology ventures in IT Services and co-founded a mobile technology provider which he ultimately led to a successful listing on the London Stock Exchange. When not balancing the books, Seán is guiding young athletes with their own balancing skills as a coach for a local hurling team in Galway.
VP Quality & Regulatory Affairs
Ann Marie Cannon is the VP of Quality and Regulatory Affairs, dedicated to delivering a high quality WhiteSwell system for treating ADHF patients. With extensive experience in developing medical device quality systems and regulatory strategies, she most recently was Director of Quality and Regulatory Affairs at Marvao Medical where she built an ISO 13485 and QSR compliant quality system, created a regulatory strategy, and led clinical trials, culminating with both CE Mark and FDA clearance. Ann Marie believes that doing things the right way with a commitment to the highest standard is vital when bringing new therapies to market. She holds a Bachelors degree in Biochemistry and a Masters degree in Biotechnology from the National University of Ireland in Galway. To facilitate clarity of thought, Ann Marie enjoys walking in the bracing air of the rugged coastline of the west of Ireland.
VP Research & Development
Ronan Keating is the VP of R&D at WhiteSwell, guiding development of an innovative treatment to target interstitial decongestion in Acute Decompensated Heart Failure patients. Ronan is an experienced R&D leader, having most recently served as CTO and founder at neoSurgical where his team developed a first of its kind absorbable tissue approximation implant, taking it from concept to regulatory approval to commercialization. Prior to this Ronan led EmboShield Embolic Protection R&D programs at Abbott Vascular and Mednova. He strongly advocates Design from First Principles and Design for Manufacture as essential for groundbreaking innovation and he strives to create products that address complex performance requirements with robust engineering and streamlined design. A Biomedical Engineer with a portfolio of circa 30 patents, he also holds a Masters Degree in Computational Fluid Dynamics. Ronan is an avid off-road cyclist who enjoys spending his free time crisscrossing the rocky landscapes of the west of Ireland and further afield whenever possible.
VP Clinical Affairs
Linda Nelson is the VP Clinical at WhiteSwell, guiding clinical strategy to demonstrate the potential for WhiteSwell’s endovenous decongestion therapy leveraging the lymphatics to target interstitial decongestion in ADHF patients. Linda has directed numerous clinical teams at Medtronic and served as VP Clinical Affairs at Respicardia. She leverages over 20 years of experience in global clinical research to develop innovative strategies for evidence collection. She enjoys building and strengthening high- performing teams and is energized by continual learning in complex environments. Linda holds both a Bachelor’s degree in nursing and an MBA. Between world travels supporting clinical studies, Linda finds time to get outdoors to kayak, hike and garden.
VP Strategic Marketing
Jill Amstutz is the VP of Strategic Marketing for WhiteSwell, where she is inspired by the opportunity to provide a valuable new approach to heart failure therapy that will help patients and clinicians. She strongly believes in the importance of developing the scientific support for new innovation. Most recently, as VP of Global Marketing at Neuravi, she launched programs including the Clot Summit which sought to advance the treatment of acute ischemic stroke through scientific research on stroke-causing thrombi. She has worked on a number of cardiovascular products at start-ups like Sadra Medical and larger corporations such as Guidant and Abbott Vascular. She has an MBA from the Stanford Graduate School of Business and a Bachelor’s degree from Princeton University. When she is not asking why, Jill enjoys hiking and being immersed in the sights, sounds and scents of nature.
VP Technical Operations
As the VP of Technical Operations, Martin Keegan oversees a world-wide network of suppliers to deliver high quality precision-engineered products. Most recently as Technical Operations Director at Boston Scientific, he was responsible for manufacturing, process optimization and validation, and led a successful technology transfer program. He brings to WhiteSwell a breadth of experience spanning endovascular medical devices to electronics, including hardware and software development. Martin delights in building cross-functional trans-national teams with an eye to excellence. He holds both a Bachelor’s and Master’s in Mechanical Engineering from National University of Ireland, Galway and is a Chartered Engineer. Fueled by fast-paced coordinated action and healthy competition, Martin dedicates time to two local water polo clubs as Team Manager.
Director Advanced Technology
Senior Engineering Manager
Senior Technology Manager
Managing Director, RA Capital
Andrew Levin is Chairman of the Board of Directors at WhiteSwell, providing guidance to help the company develop what he believes will be a potentially game-changing therapy. He is passionate about developing new therapies as a Managing Director at RA Capital Management where he spearheads a drug discovery effort that has led to the formation of several new companies. Previously he served as Vice President at H.I.G. Bioventures and as Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. When he isn’t growing companies, he spends time with his growing family.
Managing Director & Co-Founder, InCube Ventures
Andrew Farquharson is a Board member at WhiteSwell, facilitating connections, providing strategic perspective and supporting innovation. His strategic insights come from two decades of experience building, restructuring and acquiring life science companies as a founding member of InCube’s venture fund and as an advisor to InCube Labs, LLC. Andrew built a global sales force from scratch, grew revenues of synthetic DNA products to $40M in two years, and helped to negotiate a sale of Operon Technologies to QIAGEN for $150M. He holds a Masters of Business Administration from Harvard University and a Bachelor’s degree from the University of California at Berkeley. A connoisseur of craft beers, Andrew’s passion for innovation and appreciation of complexity imbue both his ventures and his leisure pursuits.
Chief Executive Officer, Lungpacer Medical Inc.
Doug Evans is on the Board of Directors at WhiteSwell, providing counsel, deep R&D experience and support to the leadership team. As CEO of Lungpacer, a company that helps protect the lungs and respiratory muscles of critically ill patients, he is devoted to addressing underserved clinical needs. His 30 years of experience includes serving as COO for Kensey Nash Corporation which was acquired for $360M by Royal DSM in 2012. He has authored over 175 patents and commercialized multiple leading-edge products in cardiology, orthopedics and general surgery. Doug holds a Bioengineering degree and MBA from Penn State, and a Master’s in Electrical Engineering and Photonics from the University of Pennsylvania. His commitment to addressing clinical challenges with improved therapy extends to his personal life, with his work as co-founder of the Cure4Cam Childhood Cancer Foundation.
Professor of Medicine, Physiology, and Cell Biology
College of Medicine Distinguished Professor
The Ohio State University, Columbus, Ohio
Director, Structural Heart Disease, Cardiac Catheterization Services
Kaplan Medical Center, Heart Institute
Director, Heart Failure, Hemodynamics and MCS Research
Cardiovascular Research Foundation (CRF)
New York, New York
We’re looking for committed, curious, creative people with a thirst for knowledge and a desire to make a significant impact on healthcare, improving therapy for ADHF.
We work in teams – in Israel, Ireland, and the US. We respect the importance of bringing different skill sets and perspectives together to generate the best solutions.
We value self-starters who are willing to go the extra mile, seek out what is needed, and take pride in the quality of their work.
Electronic Design Engineer
You are motivated by innovation that impacts lives. You excel when dealing with complex challenges, able to dive into the details while keeping an eye on the overarching objectives. An effective team player, you take the initiative and seek excellence. You have a BSc, MSc or PhD in Electronic/Computer Engineering and 3+ years of experience in electronic/hardware design. Click here if you want to explore this opportunity.
Funds Will Support Product Development and Clinical Studies of Novel Catheter-Based Technology
Adds to Portfolio of 40 Patents for Catheter-Based Technology That Leverages Power of Body’s
Natural Fluid Removal Process
Direct Interstitial Decongestion in an Animal Model of Acute-on-Chronic Ischemic Heart Failure
William T. Abraham, Michael Jonas, Ranjeet M. Dongaonkar, Beth Geist, Yukie Ueyama, Kevin Render, Brad Youngblood, William Muir, Robert Hamlin, and Carlos L. del Rio
Lymphatic Dysregulation in Patients With Heart Failure: JACC Review Topic of the Week
Marat Fudim, Husam M. Salah, Janarthanan Sathananthan, Mathieu Bernier, Waleska Pabon-Ramos, Robert S. Schwartz, Josep Rodés-Cabau, François Côté, Abubaker Khalifa, Sean A. Virani, Manesh R. Patel
Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction
Giacomo Rossitto, Sheon Mary, Christine McAllister, Karla Bianca Neves, Laura Haddow, John Paul Rocchiccioli, Ninian Nicholas Lang, Clare Louise Murphy, Rhian Merry Touyz, Mark Colquhoun Petrie, Christian Delles
1 Martens & Mullens, How to tackle congestion in acute heart failure, Korean J Intern Med 2018;33:462-473
2 Agarwal et al, Temporal Trends in Hospitalization for Acute Decompensated Heart Failure in the United States, 1998– 2011, Am J Epidemiol. 2016;183(5):462–470
3 Westenbrink et al, Heart failure specialization in Europe, European Journal of Heart Failure (2016) 18, 347–349
4 Martens & Mullens, How to tackle congestion in acute heart failure, Korean J Intern Med 2018;33:462-473
5 Arrigo et al, Optimising Heart Failure Therapies in the Acute Setting, Cardiac Failure Review 2018;4(1):38-42
6 Chioncel et al, Cardiac Failure Review 2017;3(2):122-9
7 Girerd et al, Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey, J Am Coll Cardiol HF 2018;6:273–85
8 Gheorghiade, M, Vaduganathan, M, Fonarow, G, Bonow, R, Rehospitalization for Heart Failure: Problems and Perspectives, J Am Coll Cardiol 2013;61:391–403.
9 Farmakis et al, Acute heart failure: Epidemiology and socioeconomic burden, Continuing Cardiology Education 2017;3(3)
10 Moore & Bertram, Lymphatic System Flows, Annu. Rev. Fluid Mech. 2018. 50:459–82